Abbott i-STAT 1 System Manual page 524

References
1. Maisel A, Mehra MR. Understanding B-Type Natriuretic Peptide and Its Role in Diagnosing and
Monitoring Congestive Heart Failure, Clin Cornerstone 2005, 7 Suppl 1: S7-17.
2. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive Heart Failure in the Community. A
Study of All Incident Cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-
2289.
3. Wu AH. B-Type Natriuretic Peptide and Its Clinical Utility in Patients with Heart Failure, MLO Med
Lab Obs. 2001 Oct; 33(10): 10-4.
4. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a Rapid
B-natriuretic Peptide Assay in Differentiating Congestive Heart Failure From Lung Disease in
Patients Presenting With Dyspnea. J Am Coll Cardiol 2002; 39: 202-209.
5. Cabanes L, Richaaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S, et al. Brain Natriuretic
Peptide Blood Levels in the Differential Diagnosis of Dyspnea. Chest 2001; 120: 2047-2050.
6. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-
natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity
Recording. Circulation 2002; 105: 595-601.
7. Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S, et al. Brain Natriuretic
Peptide is Stable in Whole Blood and Can Be Measured Using a Simple Rapid Assay:
Implications for Clinical Practice. Heart 1997; 78: 594-597.
8. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The
Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes. N
Engl J Med. 2001 Oct 4; 345(14): 1014-21.
9. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of Brain
Natriuretic Peptide in Risk Stratification of Patients with Congestive Heart Failure. J Am Coll
Cardiol. 2001 Dec; 38(7): 1934-41.
10. Richards AM, Lainchbury JG, Nicholls MG, Troughton RW, Yandle TG. BNP in hormone-guided
treatment of heart failure. Trends Endocrinol Metab. 2002 May-Jun; 13(4):151-5.
11. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of
Heart Failure Guided by Plasma Aminoterminal Brain Natriuretic Peptide (N-BNP) Concentrations.
Lancet. 2000 Apr 1; 355(9210): 1126-30.
12. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, Mehra MR, Peacock
WF 4th, Fonarow G, Gibler WB, Morrow DA, Hollander J; BNP Consensus Panel. BNP
Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment
monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest
Heart Fail. 2004 Sep-Oct;10 (5 Suppl 3): 1-30.
13. Davis M, Espiner E, Richards G, Billings J, Town I, Drennan NA, et al. Plasma Brain Natriuretic
Peptide in Assessment of Acute Dyspnea. Lancet 1994; 343: 440-444.
14. Remme WJ, Swedberg K, Task Force Report. Guidelines for the Diagnosis and Treatment of
Chronic Heart Failure. Eur Heart J 2001; 22: 1527-1560.
15. Maisel A, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid Measurement
of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med. 2002
Jul 18; 347(3): 161-7.
16. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-Type Natriuretic
Peptide and Echocardiographic Determination of Ejection Fraction in the Diagnosis of
Congestive Heart Failure in Patients with Acute Dyspnea. Chest. 2005 Jul; 128(1): 21-9.
BNP - 14
Art: 716969-01H Rev. Date: 01-Jul-13